EPN
Epsilon Healthcare Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-18.12%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Epsilon Healthcare Ltd. manufactures and distributes hydroponics equipment, materials, and nutrients; and develops and delivers medical cannabis. The company is headquartered in Sydney, New South Wales. The company went IPO on 2017-05-04. The firm has a diversified and vertically integrated portfolio of assets, including healthcare and pharmaceutical contract development and manufacturing. The Company’s segments include the manufacture and distribution of hydroponics equipment, materials and nutrients, and the development and delivery of medicinal cannabis. The firm owns medicinal cannabis assets, including the GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport Facility) in Southport, Australia, and the Tetra Health clinic group. The firm also provides advisory services related to medicinal cannabis. The Company’s subsidiaries include Dragon Vision Limited, Canndeo Pty Ltd, Canna Clinics Pty Ltd, THC Pharma Pty Ltd, Metra Holdings Pty Ltd, Tetra Pty Ltd, Medimar Pty Ltd and Demimar Pty Ltd.
📈 Performance
Price History
-88.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.02
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in EPN
5
📊 Total Capital Earnings
$828.84
🔃 Average investment frequency
33 weeks
💵 Average investment amount
$200
⏰ Last time a customer invested in EPN
620 days
EPN investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
40%
50k - 100k
40%
Less than 50k
20%
👶 Age of investors
18 - 25
26 - 34
40%
35 - 90
60%
🙋 Legal gender of investors
Female
60%
Male
40%
Pearlers who invest in EPN also invest in...
Cann Group Ltd. engages in the cultivation of medicinal cannabis and further processing into manufactured medicinal cannabis products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The company operates through cultivation of the medicinal cannabis segment. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.
🙌 Performance (5Yr p.a)
-19.35%
📊 Share price
$0.02 AUD
📦 LOGISTICS
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. The firm supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. The company also owns Satipharm and its patent-protected capsule technology. The firm's research, cultivation and good manufacturing practices (GMP) manufacturing facilities are located in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.
📦 LOGISTICS
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6817.34m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
9.37%
📊 Share price
$132.39 AUD
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
💸 FINANCIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.96%
📊 Share price
$136.00 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
23.37%
📊 Share price
$59.81 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Want more shares? Try these...
